Guerbet

GBT.PAPhase 3

Villepinte, FranceFounded 1926guerbet.com

Guerbet is a 100-year-old, publicly traded French pharmaceutical company focused exclusively on medical imaging. It offers a comprehensive portfolio of contrast media and solutions for X-ray, MRI, and interventional radiology, with a strategic emphasis on innovation and a proactive CSR approach. The company generates significant revenue from its commercial products, maintains a strong family-led governance, and is actively expanding indications for its key assets, such as the recent pediatric approval for Elucirem™ in Europe.

Market Cap

$54.8M

Founded

1926

Employees

2,905

Focus

Diagnostics

GBT.PA · Stock Price

USD 5.850.08 (-1.27%)

Historical price data

AI Company Overview

Technology Platform

Specialized chemistry and formulation platform for developing contrast media agents for medical imaging modalities including MRI, CT, X-ray, Ultrasound, and Interventional Radiology.

Pipeline Snapshot

50 drugs in pipeline, 10 in Phase 3

Drug	Indication	Stage
Dotarem + Gadovist	Peripheral Arterial Disease	Approved
Lipiodol UF + Saline	Infertility	Approved
Iodixanol + Ioxaglate + Bivalirudin	Coronary Artery Disease	Approved
Gadopiclenol	Prostate Cancer	Approved
gadoteric acid	Arterial Occlusive Disease	Approved

Opportunities

Growth is driven by the pediatric approval for Elucirem™, the global shift towards safer half-dose GBCAs, expansion in emerging markets with growing imaging access, and the increasing volume of minimally invasive interventional radiology procedures.

Risk Factors

Key risks include regulatory and safety scrutiny of contrast agents, intense competition from larger players, revenue concentration on key products, moderate financial leverage, and dependence on global healthcare procedure volumes and reimbursement policies.

Competitive Landscape

Guerbet competes with large imaging conglomerates like Bayer, GE Healthcare, and the pure-play specialist Bracco Imaging. Its differentiation lies in its focused expertise, innovative half-dose GBCA technology, strong interventional radiology portfolio, and stable, family-influenced long-term strategy.